DK3271392T3 - Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia - Google Patents
Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia Download PDFInfo
- Publication number
- DK3271392T3 DK3271392T3 DK16720043.5T DK16720043T DK3271392T3 DK 3271392 T3 DK3271392 T3 DK 3271392T3 DK 16720043 T DK16720043 T DK 16720043T DK 3271392 T3 DK3271392 T3 DK 3271392T3
- Authority
- DK
- Denmark
- Prior art keywords
- hyperopia
- myopia
- therapeutic
- agents
- prophylactic treatment
- Prior art date
Links
- 206010020675 Hypermetropia Diseases 0.000 title 1
- 230000004305 hyperopia Effects 0.000 title 1
- 201000006318 hyperopia Diseases 0.000 title 1
- 208000001491 myopia Diseases 0.000 title 1
- 230000004379 myopia Effects 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15000771.4A EP3070101A1 (en) | 2015-03-16 | 2015-03-16 | Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia |
PCT/EP2016/000460 WO2016146254A1 (en) | 2015-03-16 | 2016-03-15 | Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3271392T3 true DK3271392T3 (da) | 2021-08-16 |
Family
ID=52807497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16720043.5T DK3271392T3 (da) | 2015-03-16 | 2016-03-15 | Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia |
Country Status (8)
Country | Link |
---|---|
US (2) | US11008385B2 (da) |
EP (2) | EP3070101A1 (da) |
JP (2) | JP7197271B2 (da) |
KR (2) | KR20170126496A (da) |
CN (1) | CN107428812A (da) |
DK (1) | DK3271392T3 (da) |
ES (1) | ES2883244T3 (da) |
WO (1) | WO2016146254A1 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3070101A1 (en) * | 2015-03-16 | 2016-09-21 | Universität Heidelberg | Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia |
EP3532891A4 (en) * | 2016-10-25 | 2020-04-29 | Brien Holden Vision Institute Limited | DEVICES, SYSTEMS AND / OR METHODS FOR CONTROLLING SHORT-VISION |
JP7097845B2 (ja) * | 2019-04-23 | 2022-07-08 | ジェネシスヘルスケア株式会社 | 近視のリスクを判定する方法 |
KR102495473B1 (ko) * | 2020-10-06 | 2023-02-06 | 서울대학교병원 | 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000504206A (ja) * | 1995-12-22 | 2000-04-11 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 新規形態のアンフィレグリン、その製造方法および使用方法、ならびにそれを含む組成物 |
EP1449538A1 (en) | 2003-02-21 | 2004-08-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
US7449442B2 (en) * | 2005-07-12 | 2008-11-11 | Children's Medical Center Corporation | EGFR inhibitors promote axon regeneration |
ES2639056T3 (es) * | 2009-10-28 | 2017-10-25 | Abbvie Biotherapeutics Inc. | Anticuerpos anti-EGFR y sus usos |
KR102272213B1 (ko) * | 2014-07-08 | 2021-07-01 | 삼성전자주식회사 | 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도 |
CA2975362A1 (en) * | 2015-02-06 | 2016-08-11 | Navigo Proteins Gmbh | Egfr binding proteins comprising ubiquitin muteins |
EP3070101A1 (en) * | 2015-03-16 | 2016-09-21 | Universität Heidelberg | Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia |
-
2015
- 2015-03-16 EP EP15000771.4A patent/EP3070101A1/en not_active Withdrawn
-
2016
- 2016-03-15 DK DK16720043.5T patent/DK3271392T3/da active
- 2016-03-15 US US15/558,139 patent/US11008385B2/en active Active
- 2016-03-15 KR KR1020177029300A patent/KR20170126496A/ko not_active IP Right Cessation
- 2016-03-15 JP JP2017549329A patent/JP7197271B2/ja active Active
- 2016-03-15 KR KR1020217021652A patent/KR20210091826A/ko not_active Application Discontinuation
- 2016-03-15 ES ES16720043T patent/ES2883244T3/es active Active
- 2016-03-15 CN CN201680016210.7A patent/CN107428812A/zh active Pending
- 2016-03-15 EP EP16720043.5A patent/EP3271392B1/en active Active
- 2016-03-15 WO PCT/EP2016/000460 patent/WO2016146254A1/en active Application Filing
-
2021
- 2021-04-13 US US17/229,303 patent/US20210340237A1/en active Pending
- 2021-05-06 JP JP2021078584A patent/JP2021119187A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3271392B1 (en) | 2021-05-19 |
JP2018518452A (ja) | 2018-07-12 |
JP2021119187A (ja) | 2021-08-12 |
ES2883244T3 (es) | 2021-12-07 |
WO2016146254A8 (en) | 2016-11-24 |
CN107428812A (zh) | 2017-12-01 |
EP3070101A1 (en) | 2016-09-21 |
US11008385B2 (en) | 2021-05-18 |
US20210340237A1 (en) | 2021-11-04 |
EP3271392A1 (en) | 2018-01-24 |
JP7197271B2 (ja) | 2022-12-27 |
WO2016146254A1 (en) | 2016-09-22 |
KR20210091826A (ko) | 2021-07-22 |
US20190085065A1 (en) | 2019-03-21 |
KR20170126496A (ko) | 2017-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
GB201614522D0 (en) | Use of cannabinoids in the treatment of multiple myeloma | |
DK3395353T3 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
HK1219782A1 (zh) | 用於預防和/或減慢近視發展的與瞳孔大小無關的鏡片設計和方法 | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
DK3139903T3 (da) | Vandig oftalmisk opløsning og fremgangsmåde til behandling af tørre øjne-syndrom | |
DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
DK3261642T3 (da) | Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner | |
DK3556383T3 (da) | Plasminogen til anvendelse ved behandling af diabetes | |
DK3160234T3 (da) | Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst | |
DK3391902T3 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
DK3456330T3 (da) | Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer | |
DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
DK3253208T3 (da) | Kombinationsterapier til anvendelse i behandlingen af brystcancer | |
DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
DK3271392T3 (da) | Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia | |
DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner | |
IL246855A0 (en) | Materials for use in the treatment of retinitis | |
DK3307277T3 (da) | Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser |